ReviewWorld journal of oncology2026

Magnitude of Survival Benefit Associated With Tyrosine Kinase Inhibitors in Advanced Thyroid Carcinoma: A Systematic Review and Meta-Analysis Incorporating Updated Long-Term Evidence From SELECT (Lenvatinib) and COSMIC-311 (Cabozantinib) Trials.

Pushpita Roy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.